鲁抗医药同业竞争遭质疑,与新华制药“药品撞车”,谁来停产?

鹰眼IPO观察
Sep 25

经济导报记者孙罗南在资本市场上,同业竞争问题始终是关注的重点。近期,鲁抗医药(600789.SH)在2025年半年报中,就与新华制药(000756.SZ)部分药品批件重合问题披露了承诺。控股股东华鲁集团将督促双方公司按照法定程序通过:三个月内一方使用完毕库存原料及包材,并完成在手订单交货后,停止其公司生产;通过包括但不限于资产转让、调整产品结构、业务调整等方式,解决批件重合问题。承诺时间为2025...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10